Human RCT
Mensch
Wong F, et al. 2021
Improves kidney function in type 1 hepatorenal syndrome (CONFIRM trial, with albumin).
What does NOT follow: Severely ill, intensive-care population; respiratory failure was observed as a safety signal.
Peptide entry · Research other
Terlipressin
Terlivaz · Glypressin · Lysin-Vasopressin-Prodrug
Highest evidence
Human RCT
Studies recorded
1· 1 in humans
Legal status · US
PrescriptionScientific context only. Not medical advice, not a recommendation to use.
At a glance
Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz).
Researched for
Hepatorenal syndrome (HRS-1)Vasodilatory/septic shockBlood-pressure support
Official status
US: Prescription
FDA-approved (2022, Terlivaz) for hepatorenal syndrome.
At a glance
Overview
What is it?
Terlipressin is a 12-amino-acid vasopressin analog and prodrug of lysine-vasopressin. As a V1 receptor agonist it is vasoconstrictive and is approved for hepatorenal syndrome (FDA 2022, Terlivaz).
How is it meant to work? →
Terlipressin is slowly converted in the body to lysine-vasopressin by cleavage of the three N-terminal glycyl residues (reservoir effect) and activates V1 receptors. The splanchnic vasoconstriction improves renal perfusion in …
What do studies show? →
Human RCTImproves kidney function in type 1 hepatorenal syndrome (CONFIRM trial, with albumin).
What do users report?
No documented community reports.
01
Mechanism of action
Terlipressin is slowly converted in the body to lysine-vasopressin by cleavage of the three N-terminal glycyl residues (reservoir effect) and activates V1 receptors. The splanchnic vasoconstriction improves renal perfusion in hepatorenal syndrome.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
03
What the studies show
Human trial
Mensch
Acts as a slow-release vasopressin prodrug with longer duration.
What does NOT follow: Closely related to vasopressin; use only under monitoring.
05
Pharmacokinetics
No robust pharmacokinetic human data available. A model curve is not invented.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
This substance is approved (in at least one country) — use belongs in medical hands, within the approved indication and a physician-set dose.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human RCT
Respiratory complications / respiratory failure; ischemic events
Documented safety signal; requires patient selection and monitoring — not a usage instruction.
relevant (CONFIRM)
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
11
Legal status by country
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
- 1Enter the vial's substance amount (printed on the label).
- 2Enter how much solvent you add.
- 3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
14
Study register
Human RCTRandomised controlled trialn = 300
Wong F, et al. · 2021
Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome (CONFIRM)
SampleAdults with type 1 hepatorenal syndrome (HRS-1).
Findings:Higher rate of HRS reversal with terlipressin+albumin than placebo+albumin; respiratory complications as a safety signal.
Limitations:High disease severity; respiratory-failure risk requires careful patient selection.
15
Sources & method
Last reviewed
2026-06-12
Get new studies on Terlipressin
Science only, no sales. Unsubscribe anytime.
We store your email only for the newsletter. Unsubscribe anytime. Privacy